{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:44:57Z","timestamp":1793915097500,"version":"4.8.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijcard.2023.131331","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:49:40Z","timestamp":1693788580000},"page":"131331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy"],"prefix":"10.1016","volume":"391","author":[{"given":"Ashot","family":"Avagimyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Sheibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Pogosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine","family":"Mkrtchyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Yeranosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Aznauryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmen","family":"Sahaakyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ijcard.2023.131331_bb0005","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0010","doi-asserted-by":"crossref","first-page":"101591","DOI":"10.1016\/j.cpcardiol.2023.101591","article-title":"Chemotherapy induced cardiotoxicity: a state of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics","volume":"48","author":"Abdul-Rahman","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131331_bb0015","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.hfc.2022.02.002","article-title":"Clinical practice guidelines in cardio-oncology","volume":"18","author":"Leong","year":"2022","journal-title":"Heart Fail. Clin."},{"issue":"18","key":"10.1016\/j.ijcard.2023.131331_bb0025","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131331_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3293","article-title":"Mitochondrial dysfunction associated with AC mode of chemotherapy intake","volume":"41","author":"Avagimyan","year":"2020","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ijcard.2023.131331_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100994","article-title":"AC-mode of chemotherapy as a trigger of cardiac syndrome X: a case study","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2023.131331_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100932","article-title":"Hyperhomocysteinemia as a link of chemotherapy-related endothelium impairment","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2023.131331_bb0045","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ihj.2016.01.022","article-title":"Cardio-oncology: concepts and practice","volume":"68","author":"Cubbon","year":"2016","journal-title":"Indian Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.hfc.2022.02.002","article-title":"Clinical practice guidelines in cardio-oncology","volume":"18","author":"Leong","year":"2022","journal-title":"Heart Fail. Clin."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0055","first-page":"263","article-title":"Trimetazidine as a modifier of chemotherapy-induced endothelium homeostasis disturbances","volume":"14","author":"Avagimyan","year":"2022","journal-title":"Cardiol. Belarus"},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.29001\/2073-8552-2022-37-2-105-111","article-title":"Trimetazidine as a modifier of doxorubicin + cyclophosphamide induced hyperdyslipidemia","volume":"37","author":"Avagimyan","year":"2022","journal-title":"Siberian J. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0065","first-page":"785","article-title":"Relationship between chemotherapy and atrial fibrillation: clinical case","volume":"17","author":"Avagimyan","year":"2021","journal-title":"Ration Pharm. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2023.131331_bb0070","doi-asserted-by":"crossref","first-page":"706","DOI":"10.18705\/1607-419X-2021-27-6-706-712","article-title":"Chemotherapy as a possible trigger for the myocardial lipomatosis development","volume":"27","author":"Avagimyan","year":"2021","journal-title":"Arterial\u2019naya Gipertenziya"},{"key":"10.1016\/j.ijcard.2023.131331_bb0075","article-title":"Anthracycline associated disturbances of cardiovascular homeostasis","volume":"47","author":"Avagimyan","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2023.131331_bb0080","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0085","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jchf.2022.10.008","article-title":"Is dapagliflozin a cardiac anti-aging drug?","volume":"11","author":"Bayes-Genis","year":"2023","journal-title":"JACC Heart Fail."},{"issue":"6","key":"10.1016\/j.ijcard.2023.131331_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.NURSE.0000927496.48856.2f","article-title":"Using dapagliflozin in patients with heart failure","volume":"53","author":"Williams","year":"2023","journal-title":"Nursing."},{"issue":"5","key":"10.1016\/j.ijcard.2023.131331_bb0095","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.15829\/1560-4071-2020-3870","article-title":"Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data","volume":"25","author":"Kobalava","year":"2020","journal-title":"Russ. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131331_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101817","article-title":"A comprehensive guide to sodium glucose co-transport inhibitors","author":"Cunningham","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2023.131331_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101597","article-title":"Sodium-glucose Cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2023.131331_bb0110","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0115","first-page":"405","article-title":"Trimetazidine as a modifier of chemotherapy-induced cardiovascular redox-homeostasis disturbances","volume":"14","author":"Avagimyan","year":"2022","journal-title":"Cardiol. Belarus"},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.29001\/2073-8552-2022-37-2-105-111","article-title":"Trimetazidine as a modifier of doxorubicin + cyclophosphamide induced hyperdyslipidemia","volume":"37","author":"Avagimyan","year":"2022","journal-title":"Siberian J. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0125","first-page":"25","article-title":"Effect of trimetazidine on myocardial karyometry during the doxorubicin-cyclophosphamide mode of chemotherapy prescription","volume":"21","author":"Avagimyan","year":"2022","journal-title":"Med. Kuzbass"},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12012-023-09784-8","article-title":"Metformin and Dapagliflozin attenuate doxorubicin-induced acute cardiotoxicity in Wistar rats: an electrocardiographic, biochemical, and histopathological approach","volume":"23","author":"Satyam","year":"2023","journal-title":"Cardiovasc. Toxicol."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12872-017-0597-z","article-title":"Cardiac tissue oxidative stress and inflammation after vitamin D administrations in high fat- diet induced obese rats","volume":"17","author":"Farhangi","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"issue":"8","key":"10.1016\/j.ijcard.2023.131331_bb0140","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/antiox11081432","article-title":"Cardioprotective effect of acetylsalicylic acid in the myocardial ischemia-reperfusion model on oxidative stress markers levels in heart muscle and serum","volume":"11","author":"Frydrychowski","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/2045-9912.273957","article-title":"Nitric oxide detection methods in vitro and in vivo","volume":"9","author":"Goshi","year":"2019","journal-title":"Med. Gas Res."},{"issue":"10","key":"10.1016\/j.ijcard.2023.131331_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24685","article-title":"Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients","volume":"36","author":"Yu","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.20538\/1682-0363-2007-4-86-90","article-title":"Clinical-biochemical markers of myocardial lesions in premature neonates","volume":"6","author":"Zhelev","year":"2007","journal-title":"Bull. Siberian Med."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/FJC.0000000000000872","article-title":"Protective effects of spermidine against cirrhotic cardiomyopathy in bile duct-ligated rats","volume":"76","author":"Sheibani","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0165","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2106\/JBJS.16.00335","article-title":"Histological evidence of muscle degeneration in advanced human rotator cuff disease","volume":"99","author":"Gibbons","year":"2017","journal-title":"J. Bone Joint Surg. Am."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0170","doi-asserted-by":"crossref","first-page":"18772","DOI":"10.1038\/s41598-022-23466-5","article-title":"Exercise preconditioning improves electrocardiographic signs of myocardial ischemic\/hypoxic injury and malignant arrhythmias occurring after exhaustive exercise in rats","volume":"12","author":"Guo","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.18087\/cardio.2021.1.n1423","article-title":"Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries","volume":"61","author":"Lipakhtusov","year":"2021","journal-title":"Kardiologiia."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0180","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40256-023-00573-w","article-title":"Endothelial-to-mesenchymal transition: potential target of doxorubicin-induced cardiotoxicity","volume":"23","author":"Feng","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00280-019-04019-6","article-title":"Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats","volume":"85","author":"Sheibani","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.ijcard.2023.131331_bb0195","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/nu15102259","article-title":"p53 at the crossroads between doxorubicin-induced cardiotoxicity and resistance: a nutritional balancing act","volume":"15","author":"Guo","year":"2023","journal-title":"Nutrients."},{"key":"10.1016\/j.ijcard.2023.131331_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172818","article-title":"Effects of doxorubicin on the heart: from molecular mechanisms to intervention strategies","volume":"866","author":"Prathumsap","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0205","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/pharmaceutics15041182","article-title":"Recent advances in mitochondrial fission\/fusion-targeted therapy in doxorubicin-induced cardiotoxicity","volume":"15","author":"Maneechote","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ijcard.2023.131331_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0215","article-title":"Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"10.1016\/j.ijcard.2023.131331_bb0220","first-page":"34","article-title":"Cardiotoxicity of cyclophosphamide: current state of the problem","volume":"3","author":"Avagimyan","year":"2022","journal-title":"Exp. Clin. Med. Georgia"},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ab.2016.10.021","article-title":"Assessment of lipid peroxidation by measuring malondialdehyde and relatives in biological samples: analytical and biological challenges","volume":"524","author":"Tsikas","year":"2017","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0230","first-page":"406","article-title":"Anti-inflammatory and Antioxidative effects of Sumatriptan against doxorubicin-induced cardiotoxicity in rat","volume":"59","author":"Sheibani","year":"2021","journal-title":"Acta Med. Iran"},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0235","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","article-title":"Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches","volume":"22","author":"Sheibani","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.ijcard.2023.131331_bb0240","first-page":"6305735","article-title":"The SGLT-2 inhibitor Dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE\u2212\/\u2212 mice","author":"Leng","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ijcard.2023.131331_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108964","article-title":"Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats","volume":"116","author":"Zeng","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijcard.2023.131331_bb0250","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0255","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41569-022-00739-0","article-title":"Mechanisms and consequences of endothelial cell senescence","volume":"20","author":"Bloom","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2023.131331_bb0260","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.3390\/ijms24054321","article-title":"Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure","volume":"24","author":"Tsigkou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijcard.2023.131331_bb0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/CRD.0b013e318283f65a","article-title":"Endothelin in coronary artery disease and myocardial infarction","volume":"21","author":"Kolettis","year":"2013","journal-title":"Cardiol. Rev."},{"issue":"7","key":"10.1016\/j.ijcard.2023.131331_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101686","article-title":"New dual endothelin receptor antagonist Aprocitentan in hypertension: a systematic review and Meta-analysis","volume":"48","author":"Mahfooz","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2023.131331_bb0275","first-page":"4070","article-title":"Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium","volume":"11","author":"Todorova","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijcard.2023.131331_bb0280","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000512771","article-title":"Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction","volume":"146","author":"Grakova","year":"2021","journal-title":"Cardiology."},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ccc.2019.12.009","article-title":"Nitric oxide and endothelial dysfunction","volume":"36","author":"Cyr","year":"2020","journal-title":"Crit. Care Clin."},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.20538\/1682-0363-2019-1-60-75","article-title":"Monocytes and cancer: promising role as a diagnostic marker and application in therapy","volume":"18","author":"Patysheva","year":"2019","journal-title":"Bull. Sib. Med."},{"key":"10.1016\/j.ijcard.2023.131331_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114576","article-title":"Molecular mechanisms of endothelial remodeling under doxorubicin treatment","volume":"162","author":"Podyacheva","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijcard.2023.131331_bb0300","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2022.01.013","article-title":"Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: what place on the pedestal?","volume":"350","author":"Grakova","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131331_bb0305","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2018.00430","article-title":"C-reactive protein in Atherothrombosis and angiogenesis","volume":"9","author":"Badimon","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ijcard.2023.131331_bb0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.20538\/1682-0363-2022-2-186-194","article-title":"Mechanisms of vascular aging","volume":"21","author":"Stakhneva","year":"2022","journal-title":"Bull. Sib. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0315","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cmet.2022.11.001","article-title":"Meta-hallmarks of aging and cancer","volume":"35","author":"L\u00f3pez-Ot\u00edn","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.ijcard.2023.131331_bb0320","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1093\/eurheartj\/ehz928","article-title":"Cardio-oncology: low-grade inflammation as a common pathway of cancer and cardiovascular disease","volume":"40","author":"L\u00fcscher","year":"2019","journal-title":"Eur. Heart J."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2023.131331_bb0325","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ihj.2016.01.022","article-title":"Cardio-oncology: concepts and practice","volume":"68","author":"Cubbon","year":"2016","journal-title":"Indian Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12944-022-01694-y","article-title":"Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?","volume":"21","author":"Avbrahams","year":"2022","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ijcard.2023.131331_bb0335","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bcp.2018.02.018","article-title":"Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction","volume":"150","author":"Sonowal","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcard.2023.131331_bb0340","doi-asserted-by":"crossref","first-page":"107","DOI":"10.56936\/18290825-2022.16.4-107","article-title":"Perivascular adipose tissue \u2013 is an orchestrator of cardiovascular disturbances sequel","volume":"16","author":"Aznauryan","year":"2022","journal-title":"New Armen Med. J."},{"key":"10.1016\/j.ijcard.2023.131331_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102120","article-title":"Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells","volume":"46","author":"Pan","year":"2021","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.ijcard.2023.131331_bb0350","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13104-017-2726-2","article-title":"Role of metabolites of cyclophosphamide in cardiotoxicity","volume":"10","author":"Kurauchi","year":"2017","journal-title":"BMC Res. Notes"},{"issue":"29","key":"10.1016\/j.ijcard.2023.131331_bb0355","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2174\/1568026621666210813112935","article-title":"Natural bioactive as a potential therapeutic approach for the Management of Cyclophosphamide-induced Cardiotoxicity","volume":"21","author":"Iqubal","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ijcard.2023.131331_bb0360","article-title":"The neglected significance of \u201cantioxidative stress\u201d","volume":"480895","author":"Poljsak","year":"2012","journal-title":"Oxid. Med. Cell Lo\u0451ngev"},{"issue":"11","key":"10.1016\/j.ijcard.2023.131331_bb0365","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.ijcard.2023.131331_bb0370","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"9","key":"10.1016\/j.ijcard.2023.131331_bb0375","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.15829\/1560-4071-2021-4703","article-title":"Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy","volume":"26","author":"Vasyuk","year":"2021","journal-title":"Russ. J. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcard.2023.131331_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101227","article-title":"Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022","volume":"48","author":"Shi","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131331_bb0385","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323012871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323012871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:23:13Z","timestamp":1760786593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323012871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":77,"alternative-id":["S0167527323012871"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131331","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"131331"}}